EU and US could reach trade deal this weekend - Reuters
Investing.com -- LifeMD Inc (NASDAQ:LFMD) stock rose 4.3% following Novo Nordisk’s (NYSE:NVO) announcement that it will continue its collaboration with the telehealth provider to offer patients access to FDA-approved Wegovy through NovoCare Pharmacy.
Novo Nordisk confirmed that its partnerships with LifeMD and Ro will continue as the pharmaceutical giant expands patient access to its weight-loss drug Wegovy. The company also announced a new collaboration with WeightWatchers beginning July 1, 2025, which will work with CenterWell Pharmacy to manage prescription fulfillment.
The Danish drugmaker emphasized that these partnerships are based on "their commitment to providing safe and effective medical treatment for patients living with chronic diseases." This news comes after Novo Nordisk recently ended its collaboration with LifeMD competitor Hims & Hers Health.
Starting July 1, Novo Nordisk will introduce a new cash-offer price of $299 for Wegovy, available through July 31, 2025. This offer is designed for self-paying patients who are new to the Wegovy savings program or haven’t previously filled prescriptions through NovoCare Pharmacy. After July, the price for self-paying patients will increase to $499 per month.
Novo Nordisk has made all doses of FDA-approved Wegovy fully available nationwide and continues to take legal action against entities selling unauthorized "semaglutide" products. The company has filed nearly 120 lawsuits across 34 states against those unlawfully marketing or selling knockoff drugs.
"We understand that how people choose to receive care is changing," said Dave Moore, Executive Vice President of U.S. Operations at Novo Nordisk Inc. "We will continue to pursue and build on agreements with companies that share our values and refine initiatives that help improve access to our FDA-approved medicines for patients."
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.